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Background: Nontuberculous mycobacteria (NTM) are an emerging threat to cystic ﬁbrosis (CF) patients but their epidemiology is not well
described.
Methods: In this retrospective observational study we identiﬁed all Scandinavian CF patients with a positive NTM culture from airway secretions
from 2000 to the end of 2012 and used national CF databases to describe microbiological and clinical characteristics.
Results: During the 13-year period 157 (11%) CF patients were culture positive for NTM at least once. Mycobacterium abscessus complex
(MABSC) (45%) and Mycobacterium avium complex (MAC) (32%) were the predominant species with geographical differences in distribution.
Younger patients were more prone to MABSC (p b 0.01). Despite treatment, less than one-third of MABSC patients with repeated positive
cultures cleared their infection and a quarter had a lung transplant or died.
Conclusion: NTM are signiﬁcant CF pathogens and are becoming more prevalent in Scandinavia. MABSC and MAC appear to target distinct
patient groups. Having multiple positive cultures despite treatment conveys a poor outcome.
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).Keywords: Mycobacterium abscessus; Mycobacterium avium; Prevalence; Susceptibility⁎ Corresponding author at: Copenhagen Cystic Fibrosis Center, Department
of Infectious Diseases 8632, Copenhagen University Hospital Rigshospitalet,
Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.
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The clinical significance of a nontuberculous mycobacteria
(NTM) positive culture from airway secretions of cystic fibrosis
(CF) patients remains uncertain [1]. For some, a positive NTMCystic Fibrosis Society. This is an open access article under the CC BY license
47T. Qvist et al. / Journal of Cystic Fibrosis 14 (2015) 46–52culture coincides with clinical deterioration, while for others,
culture positivity seems to be transient and of no clinical
importance [1]. If little is known about the significance of a
positive culture [2], even less is known about patient susceptibil-
ity and risk factors for acquisition [3]. Understanding the risks
associated with infection is particularly important due to the
well-described adverse effects of current NTM treatment
regimens [4,5]. In light of the recent attention NTM is receiving
as a threat to CF patients [6], we examined the situation in
Scandinavia. The objective of this retrospective multicenter study
was to describe the scope and importance of NTM in the complete
Scandinavian CF population.We thus report, for the first time, the
prevalence of NTM among all CF patients in Scandinavia;
geographical differences in species distribution; explore risk
factors for acquisition; and describe outcomes including devel-
opment of end-stage-lung-disease (ESLD).
2. Methods
2.1. Setting
Scandinavia consists of Denmark, Norway and Sweden and
has a total population of 20.2 million people [7], with an
estimated CF incidence of 1 in 4900 live births [8,9] and
generally a high proportion of patients who are homozygous for
the F508del mutation in the CF transmembrane conductance
regulator (CFTR) gene (87%, 71%, 67% for Denmark, Norway,
Sweden) [10]. All CF patients receive treatment at one of eight
CF centers, where patients are seen on an outpatient basis on
average eight times annually. Patients with less than 8 scheduled
annual visits (Norway, Sweden), were seen additionally at local
hospitals as part of shared care agreements, implemented to
reduce long distance travel. With the exception of Denmark,
patients were screened for NTM annually either by expectorated
sputum, laryngeal suction or bronchoalveolar lavage (BAL),
starting at age 6 to 10 years of age with some variability in
screening policies over time and between centers. In Denmark,
systematic annual screening was introduced in 2011; prior to this,
patients were only cultured for NTM upon clinical suspicion.
During visits, anthropometric data and forced expiratory volume
in 1 s (FEV1) were recorded. Pulmonary function tests were
performed according to international recommendations [11],
measuring FEV1, expressed as a percentage of predicted values
for sex and height, using reference equations from Wang or
Hankinson [12,13].
2.2. NTM isolation
Depending on CF center, sputum and BAL samples were
pretreated with SDS-NaOH, a cocktail of antibiotics (amphotericin
B, carbenicillin, polymyxin B-sulfate and trimethoprim-lactate), or
5% oxalic acid. Samples were then cultured for mycobacteria on
either Löwenstein–Jensen egg medium, Bactec 460™ culture
system, MGIT™ (Mycobacteria Growth Indicator Tube) 960
system or Burkholderia cepacia selective agar [14]. In most
centers, more than one method of decontamination and culture
was used reflecting ongoing advances in methodology. Positivecultures were identified to species-level by 16-23S spacer array
technique, sequencing of the rpoB gene, hybridization and/or
growth ability on Löwenstein–Jensen slants with 5% NaCl. In
some centers, the GenoType Mycobacterium CM and AS tests
[15] and DNA sequencing of the hsp65 gene [16] were used.2.3. Prevalence study
In the first part of the study we aimed to describe the
prevalence as well as geographical and species distribution of
NTM in Scandinavia. CF registries and microbiological databases
in Denmark, Norway and Sweden were queried for any patient
with CF, who had at least one positive NTM airway culture from
January 2000 to December 2012. The American Thoracic Society
(ATS) and Infectious Disease Society of America (IDSA)'s
microbiological criteria were used to classify patients [17],
dividing NTM patients into those with only a single positive
sputum culture, and those with N1 positive sputum culture or at
least one positive BAL.2.4. Comparison with background Scandinavian
CF population
In the second part of the study we aimed to describe the
clinical characteristics of patients at time of first NTM positive
culture. For comparison purposes, similar data from a recent
clinical study of the Scandinavian CF population were
captured [10], including sex, age, and CFTR mutation data.
Prior Gram-negative infection, pancreatic insufficiency (PI),
azithromycin and steroid maintenance treatment as well as
CF-related diabetes mellitus (CFRD) diagnosed using previ-
ously published criteria [18], were all also included at time of
first positive NTM culture for cases, and in the calendar year
2002 for the background population. We stratified the analysis
according to NTM species to examine whether different NTM
species were more common in CF patients with particular
clinical characteristics.2.5. Outcome study
The third part of the study aimed to describe the clinical
impact of NTM disease. We therefore examined number of
positive cultures, NTM treatment (yes, no), duration of
infection, development of end stage lung disease (ESLD)
and clearance of NTM, stratified by age group (b20 years vs.
≥ 20 years of age), gender, NTM species and ATS/IDSA
criteria. ESLD was defined as lung transplantation or death,
whichever came first. To distinguish patients where NTM
involvement was judged to have played a role in the
development of ESLD, data was further subdivided depending
on clinical certainty of NTM involvement in death or lung
transplantation. Time of NTM clearance was defined as the
first calendar year without culture positivity, if the patient was
off treatment.
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Baseline data were calculated as medians and interquartile
ranges (IQR) for continuous variables, and percentages for
categorical variables. Cross sectional group comparisons were
made using analysis of variance or KruskalWallis non-parametric
tests. Differences in characteristics between groups were
evaluated using the Chi-square test and binary logistic regression
was used to adjust for statistically significant covariates in the
outcome analysis. A level of 0.05 was set for statistical
significance. All statistical analyses were performed using SPSS
version 19.0 (SPSS Inc., Chicago, IL).
2.7. Ethical considerations
Ethical approval was not required for the Scandinavian data
collection. Data was housed in Copenhagen, Denmark as approved
by the Danish Data Protection Agency (File: 2007-58-0015).
3. Results
3.1. Prevalence study
From 2000 to the end of 2012, Scandinavia's CF population
increased from 1197 to 1411 individuals. During this time, 14,385
NTM cultures were performed on 1270 patients giving a mean of
11 (range: 1–60) cultures per patient during the 13-year period.
NTMwas cultured 1193 times from 157 subjects giving an overall
period prevalence of patients with at least one positive NTM
culture of 11% (157/1411). The annual number of new patients
with NTM increased during the study period with a mean of 8 new
cases annually from 2000–2006 to a mean of 14.5 new cases
annually between 2007 and 2012. However the CF population in
Scandinavia also grew 15% during the period. Fig. 1 shows the
number of new cases adjusted for annual population size (NTM
incidence) and stratified by country. Norway and Sweden thus did
not see a consistently rising incidence over the period, but rather a
fluctuating number of new cases with notable peaks in 2005, 2007
and 2008. Denmark saw a sharp increase in incidence in the last
two years of the period, but this coincided with the implementa-
tion of intensified screening procedures, going from only testing0
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Fig. 1. New cases of patients with at least one nontuberculous mypatients suspected of NTM infection, to introducing annual
screening of all patients. Norway and Sweden performed annual
screening throughout the study period. In 7 out of 8 CF centers,
pediatric patients had sputum screened starting at 6–10 years of
age. One center (Copenhagen) used laryngeal suction starting
from infancy. The annual prevalence rate of Mycobacterium
abscessus complex (MABSC) andMycobacterium avium complex
(MAC) increased in all three countries as patients accumulated
throughout the study period. Thus in 2000 1.7% of the
Scandinavian CF population fulfilled the ATS/IDSA microbio-
logical criteria, a figure which grew to 4.1% by the end of 2012.
Fig. 2 illustrates the steady rise in the number of NTM patients
each year of the study period. NTM were recovered from subjects
in all participating centers, but period prevalence rates varied by
geographic location, ranging from 3% in Aarhus, Denmark to
28% in Gothenburg, Sweden. Likewise the distribution of species
varied among sites, with MABSC being the predominant NTM in
Denmark and MAC being more dominant in Norway and in
Sweden, which also had a higher rate of patients with two different
NTM species, typically a combination of MABSC and MAC
(Table 1). Overall, 70 patients grew only MABSC making it
the most common NTM species (45%), followed byMAC, which
was cultured exclusively from 51 patients (32%). An additional
17 patients had both MABSC and MAC (11%). Ten patients had
NTM species other than MASBC and MAC including Mycobac-
terium lentiflavum, Mycobacterium malmoense, Mycobacterium
fortuitum, Mycobacterium kansasii or unknown mycobacterial
species. The remaining nine patients had combinations of the
NTM species mentioned above or combinations with isolates of
Mycobacterium triplex, Mycobacterium nebraskense and Myco-
bacterium gordonae. Subspeciation of MABSC was not intro-
duced in Scandinavia until after 2012 and subspecies of MAC
could not be reliably compared due to historical differences in
taxonomy between centers. SomeMABSC cultures from the early
period were classified asMycobacterium chelonae, but were later
reclassified as MABSC in accordance with changes in mycobac-
terial taxonomy [19].
The median age of patients at time of first positive NTM
culture was 19 years (IQR: 13–29 years) and 55% were male.
The median %FEV1 was 82 (IQR: 61–97), and median Z-BMI
was −0.4 (IQR: −0.9–0.5). Seventy-one patients (45%) had aDenmark
Sweden
Norway
cobacteria positive culture among CF patients in Scandinavia.
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Fig. 2. Number of CF patients fulfilling ATS/IDSA microbiological criteria for
nontuberculous mycobacteria infection in Scandinavia from 2000 to 2012.
Table 2
Characteristics of NTM cases at time of first positive culture compared to a
cross section of the background Scandinavian CF population.
NTM cases
2000–2012
CF population
in 2002
p-Value
n = 157 n = 989 a
Median age, y (IQR) 19 (13–22) 17 (10–27) 0.23
Female, % 45 48 0.48
Homozygous for F508del
mutation, %
61 53 0.10
Median FEV1% of
predicted, (IQR)
82 (61–97) 80 (58–95) 0.44
Median Z-BMI (IQR) −0.4 (−0.9–0.5) −0.2 (−1.0–0.5) 0.43
Pancreatic insufficiency, n (%) 87 90 0.22
CFRD, % 23 11 b0.01
Chronic Gram-negative
infection, %
49 44 0.29
Continuous macrolides, % 24 24 0.88
Oral steroid treatment, % 7 4 0.11
a Captured from cross sectional study of 86% of the Scandinavian CF
population in 2002, including NTM cases who could not be distinguished.
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Pseudomonas aeruginosa (34%). Seventy of the 157 patients
had data available on azithromycin use. Of these, 19 patients
(27%) were in continuous azithromycin treatment at the time of
first positive NTM culture.CF = cystic fibrosis, BMI = body mass index, and CFRD = cystic fibrosis
related diabetes.3.2. Comparison with background Scandinavian
CF population
The characteristics of the 157 NTM patients were compared
with a previous cross sectional study of 989 patients, representing
86% of the CF population in Scandinavia in 2002 [10]. NTM
cases were more likely than the background CF population
to have diabetes (23% vs. 11%, p b 0.001), but were not
distinguishable in other respects. This finding remained signif-
icant after adjustment for age and when including only patients
who fulfilled ATS/IDSA microbiological criteria (p b 0.01)
(Table 2).
To compare the characteristics of patients with MABSC and
MAC, patients with other NTM species (n = 10) and co-infected
patients (n = 26) were excluded (Table 3).MABSCwas acquired
at an earlier age than MAC (median age 17 vs. 22 years,
p b 0.01) (Fig. 3) and there was a trend towardsMABSC patients
being more likely to have pancreatic insufficiency (94% vs. 84%,Table 1
Species and geographical distribution of nontuberculous mycobacteria in Scandinav
Country CF Center NTM prevalence
2000–2012
MABSC (% a)
Denmark Aarhus 3% 4 (80)
Copenhagen 13% 29 (69)
Norway Bergen 5% 1 (50)
Oslo 4% 3 (30)
Sweden Uppsala 5% 2 (40)
Stockholm 13% 10 (34)
Gothenburg 28% 15 (33)
Lund 11% 5 (28)
Total 11% 70 (45)
CF = cystic fibrosis, NTM = nontuberculous mycobacteria, MABSC = M. abscessu
a Patients exclusively infected with MABSC expressed as % of total NTM cases.
b M. lentiflavum (n = 2), M. malmoense (n = 2), M. fortuitum (n = 1), M. kansas
c 17/26 were combinations of exclusively MABSC and MAC.p = 0.07). No other significant differences in clinical character-
istics could be identified (Tables 2 and 3).
3.3. Outcome study
Of the 157 NTM patients, 125 (80%) fulfilled ATS/IDSA
microbiological criteria during the study period. These patients
were NTM positive for a total of 472 person-years, of which the
majority was contributed by 69 patients, who had ≥5 positive
NTM cultures (Table 3).
The median duration of infection was 2 years (IQR:
1–6 years) for all 125 patients fulfilling ATS/IDSA microbi-
ological criteria and 5 years (IQR: 2–9) for the group with ≥5
positive cultures (p b 0.001). NTM acquisition before the age
of 20 (NTM b 20 years) was more common in MABSC
patients compared to MAC (88% vs. 38% p b 0.001) and in
patients who went to fulfill ATS/IDSA microbiological criteriaia.
No. of patients with ≥1 Positive culture
MAC Other NTM species b More than one NTM species c
0 0 1
12 0 1
1 0 0
5 1 1
1 1 1
7 4 8
20 0 10
5 4 4
51 10 26
s complex; MAC = M. avium complex.
ii (n = 1) or unknown species (n = 4).
Table 3
Characteristics of MABSC and MAC positive CF patients in Scandinavia.
Characteristic at time of first
positive isolate
Patients with
MABSC
Patients with
MAC
p-Value
(n = 70) (n = 51)
Female, % 52 38 0.13
Median age (IQR), y 17 (12–21) 22 (15–32) b0.01
Homozygous for F508del
mutation, %
64 68 0.63
Median %FEV1 of pred. (IQR) 83 (57–96) 76 (62–95) 0.18
Median BMI kg/m2 (IQR) 19 (17–21) 20 (19–23) 0.11
Z-BMI −0.1 (−1.0–0.6) −0.4 (−1.0–0.5) 0.77
Pancreatic insufficiency, % 94 84 0.07
CFRD, % 22 18 0.62
Chronic Gram negative
infection, %
59 69 0.33
Aspergillus infection a, % 48 55 0.13
ABPA, % 25 21 0.64
Azithromycin treatment, % 18 25 0.19
Oral or IV steroid treatment, % 10 7 0.63
MABSC = M. abscessus complex; MAC = M. avium complex; NTM =
nontuberculous mycobacteria;
IQR = interquartile range, CFRD = cystic fibrosis related diabetes.
a Deﬁned as having positive Aspergillus cultures at least 6 months of
a calendar year; ABPA = allergic bronchopulmonary aspergillosis, deﬁned
according to consensus criteria [33].
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cultures (IQR: 2–13) compared to a median of 3 positive
cultures (IQR: 1–6) (p = 0.01) in the group who acquired NTM
as adults. However, the association between NTM b 20 years
and fulfilling ATS/IDSA criteria was no longer significant,
when patients were stratified for NTM species. No gender
differences were observed.
Out of the 107 patients (86%) for whom treatment data were
available, 79 (74%) received some form of NTM treatment.
Forty-nine patients (39%) had a successful outcome i.e. became
culture negative, either following treatment (n = 24/125, 19%),
or without treatment (n = 18/125, 14%). Of the 58 patients (46%
of those fulfilling ATS criteria) who did not clear their NTM by
the end of the study period, 46 (79%) had received NTM
treatment. Overall more patients with MABSC than with MAC
received treatment for their infection (72% vs. 44%, p = 0.02). A
higher proportion of those who acquired NTM before the age of
20 ended up developing ESLD (19% vs. 13%), but this was not a0
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Fig. 3. Distribution of Mycobacterium abscessus complex (MABSC) and
Mycobacterium avium complex (MAC) positive patients according to age at
time of first isolate.statistically significant difference (p = 0.32). MABSC patients
with a history of more than 4 positive cultures were most likely to
have received treatment (93%), least likely to clear infection
(16%) and had the highest rate of ESLD (26%), although these
findings did not reach statistical significance (Table 4).
4. Discussion
In the Scandinavian CF population MABSC appears to be
more common in younger patients. By contrast MAC is generally
acquired later in life and possibly by patients with a less severe
form of CF as indicated by a trend towards a higher proportion of
pancreatic sufficiency in this group. This corroborates a previous
study from France [20]. Furthermore we suggest a role of
diabetes as a risk factor for NTM acquisition; a finding that
warrants further exploration. MABSC patients with repeated
positive cultures had the worst outcomes with one-forth
progressing to ESLD.
4.1. Prevalence
In Scandinavia, reported incidence rates of MABSC increased
in the two CF centers that introduced intensified screening, while
fluctuations in incidence were seen in six other centers with
considerable geographical and species variation. Still, due to an
accumulation effect, the total number of patients with NTM
increased, so that by the end of the study period 11% of the
Scandinavian CF population had been culture positive at least
once. In comparison, two smaller prospective studies of NTM
from 1990 (Sweden) [21] and 1993 (Denmark) [22], found NTM
prevalence rates of 9% and 4%, respectively. Since 1980, 19
studies from primarily the US and Europe have reported
prevalence rates of NTM among CF patients [3], with large
geographical and inter-center variation (median 9% IQR: 6% −
14%). Likewise, in Scandinavia we see considerable geograph-
ical variation in the prevalence of NTM (range per center: 3%–
28%). MABSC was the predominant NTM species in Denmark,
whereas MAC was slightly more prevalent in Norway and
Sweden. While environmental factors are often mentioned as a
possible explanation for differences in species distribution [23],
differences in culture frequency and technique between centers
may explain the differences observed. For example one center
which only reported MABSC cases, primarily used a culture
technique suitable for fast growing mycobacteria [14]; an
approach likely to miss MAC. Previously, automated liquid
culture platforms have been reported to cause reduced recovery
of NTM and produce a high number of contaminated cultures
[24], particularly from CF patients [25].
4.2. Risk of NTM acquisition
MABSC patients were younger than MAC patients and we
observed a trend towards a higher likelihood of pancreatic
insufficiency among MABSC patients. This corroborates the
findings of a French nested case–control by Catherinot et al. from
2013 [20]. The reasons for these differences remain unknown. To
further explore association between clinical characteristics and
Table 4
Outcomes of 125 patients with more than 1 positive culture for nontuberculous mycobacteria from 2000 to 2012.
MABSC MAC Other NTM/co-infected a
2–4 pos ≥5 pos 2–4 pos ≥5 pos 2–4 pos ≥5 pos
Number of patients 23 34 17 19 16 16
Median duration of infection, y 1 5 1 3 2 6
Received NTM treatment, n (%) b 13/19 (68%) 28/30 (93%) 5/14 (36%) 15/17 (88%) 4/11 (36%) 14/16 (88%)
Cleared infection, n (%) c 8/15 (53%) 5/31 (16%) 10/17 (59%) 8/19 (42%) 8/16 (50%) 8/16 (50%)
ESLD, all, n (%) 5 (22%) 9 (26%) 1 (6%) 4 (16%) 3 (19%) 2 (13%)
ESLD judged NTM related, n (%) 1 (4%) 8 (24%) 0 3 (16%) 1 (6%) 2 (13%)
a 32 patients who had NTM species other than MABSC and MAC or combinations of more than one NTM species.
b Data missing for 18 patients.
c 11 patients excluded due to too recent infection, MABSC = M. abscessus complex, MAC = M. avium complex, IQR = Interquartile range, ESLD = end stage
lung disease, defined as death or lung transplantation during the study period.
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population. Despite a suboptimal design, where NTM patients
comprised both the case and a small part of the control group, the
analysis suggested that NTM patients in Scandinavia were more
likely to have diabetes than the background CF population
despite a similar median age. This link has been shown
previously in a smaller CF patient sample [26] and warrants
further exploration, ideally in a prospective design. The fact that
no other statistically significant associations were observed
should be interpreted with caution, as the design tended to
underestimate any association. Likewise, any risk-inferring or
protective role of azithromycin maintenance therapy at time of
first positive culture could not be determined. The role
azithromycin exposure may play in causing NTM disease
remains controversial [27,28]. Azithromycin policies varied
between the centers during the study period. In four centers,
azithromycin was given to all CF patients with chronic
P. aeruginosa lung infection and the remaining centers had a
variable azithromycin policy as previously described [10].Idea and conceptualization: Qvist T, Pressler T, Jönsson B, Gilljam M,
Katzenstein TL
Microbiological data collection: Svahn A, Wang M, Jönsson B, Høiby N,
Qvist T
Clinical data collection: Kötz K, Hansson L, Hollsing A, Finstad PL,
Laerum BL, L Hansson, Jönsson B, Gilljam M,
Jensen-Fangel S, Katzenstein TL, Qvist T
Data analysis: Qvist T, Hansen CR, Taylor-Robinson D
All authors participated in revising the manuscript and have approved the final4.3. Outcomes
MABSC patients had a higher number of positive cultures
and were more likely to receive treatment, a finding in line with
the general consensus that MABSC infection is associated with
clinical deterioration [26]. Likewise MABSC patients with a
history of more than 4 positive cultures were the least likely to
clear infection and had the highest rate of ESLD.
Study limitations include the retrospective design and lack
of data on smear positivity and colony morphology, factors
which have been identified as important in previous studies
[29–32]. Furthermore our outcome analysis did not include
important factors such as lung function data; subsequent
acquisition of other infections; the specific nature of NTM
treatment regimens and additionally ATS/IDSA radiological
criteria could not be applied; all due to limitations in study
design. However, Scandinavia provides an ideal setting for CF
studies as treatment is restricted to eight medical centers and all
CF patients are seen with an unparalleled frequency. The
primary strength of this study is thus the inclusion of threecomplete national CF populations in a comprehensive 13-year
study period.
4.4. Conclusion
This study confirms that NTM are important CF pathogens in
Scandinavia with 11% of patients having been culture positive at
least once between 2000 and the end of 2012. NTM species
exhibit geographical differences and MABSC and MAC appear
to target distinct CF patient subpopulations, with younger,
pancreatic insufficient patients being more prone to MABSC
culture positivity. Despite treatment, less than a third of MABSC
patients with repeated positive cultures cleared their infection and
one-fourth were eventually lung transplanted or died.
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